79 related articles for article (PubMed ID: 10938525)
41. The elevated peripheral white blood count.
Bolwell BJ
Cleve Clin J Med; 1993; 60(4):267-8. PubMed ID: 8339449
[No Abstract] [Full Text] [Related]
42. Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia.
Preisler HD; Gessner T; Azarnia N; Bolanowska W; Epstein J; Early AP; D'Arrigo P; Vogler R; Winton L; Chervenik P
Cancer Chemother Pharmacol; 1984; 12(2):125-30. PubMed ID: 6697426
[TBL] [Abstract][Full Text] [Related]
43. Hypocholesterolemia as a manifestation of disease activity in chronic myelocytic leukemia.
Gilbert HS; Ginsberg H
Cancer; 1983 Apr; 51(8):1428-33. PubMed ID: 6572087
[TBL] [Abstract][Full Text] [Related]
44. Drug targeting using low density lipoprotein (LDL): physicochemical factors affecting drug loading into LDL particles.
Kader A; Davis PJ; Kara M; Liu H
J Control Release; 1998 Nov; 55(2-3):231-43. PubMed ID: 9795069
[TBL] [Abstract][Full Text] [Related]
45. Role of red blood cells in pharmacokinetics of chemotherapeutic agents.
Schrijvers D; Highley M; De Bruyn E; Van Oosterom AT; Vermorken JB
Anticancer Drugs; 1999 Feb; 10(2):147-53. PubMed ID: 10211544
[TBL] [Abstract][Full Text] [Related]
46. Treatment of cancer patients with a low-density-lipoprotein delivery vehicle containing a cytotoxic drug.
Filipowska D; Filipowski T; Morelowska B; Kazanowska W; Laudanski T; Lapinjoki S; Akerlund M; Breeze A
Cancer Chemother Pharmacol; 1992; 29(5):396-400. PubMed ID: 1551179
[TBL] [Abstract][Full Text] [Related]
47. Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells.
Firestone RA
Bioconjug Chem; 1994; 5(2):105-13. PubMed ID: 8031872
[No Abstract] [Full Text] [Related]
48. Recent Development of LDL-Based Nanoparticles for Cancer Therapy.
He B; Yang Q
Pharmaceuticals (Basel); 2022 Dec; 16(1):. PubMed ID: 36678515
[TBL] [Abstract][Full Text] [Related]
49. Elucidating the structural organization of a novel low-density lipoprotein nanoparticle reconstituted with docosahexaenoic acid.
Mulik RS; Zheng H; Pichumani K; Ratnakar J; Jiang QX; Corbin IR
Chem Phys Lipids; 2017 Apr; 204():65-75. PubMed ID: 28342772
[TBL] [Abstract][Full Text] [Related]
50. Lipoprotein-Related and Apolipoprotein-Mediated Delivery Systems for Drug Targeting and Imaging.
Almer G; Mangge H; Zimmer A; Prassl R
Curr Med Chem; 2015; 22(31):3631-51. PubMed ID: 26180001
[TBL] [Abstract][Full Text] [Related]
51. Low density lipoprotein bionanoparticles: From cholesterol transport to delivery of anti-cancer drugs.
Harisa GI; Alanazi FK
Saudi Pharm J; 2014 Dec; 22(6):504-15. PubMed ID: 25561862
[TBL] [Abstract][Full Text] [Related]
52. Targeted nanoparticles for pediatric leukemia therapy.
Basha R; Sabnis N; Heym K; Bowman WP; Lacko AG
Front Oncol; 2014; 4():101. PubMed ID: 24860784
[TBL] [Abstract][Full Text] [Related]
53. Low-density lipoprotein-mediated delivery of docosahexaenoic acid selectively kills murine liver cancer cells.
Reynolds L; Mulik RS; Wen X; Dilip A; Corbin IR
Nanomedicine (Lond); 2014 Jul; 9(14):2123-41. PubMed ID: 24397600
[TBL] [Abstract][Full Text] [Related]
54. A critical review of lipid-based nanoparticles for taxane delivery.
Feng L; Mumper RJ
Cancer Lett; 2013 Jul; 334(2):157-75. PubMed ID: 22796606
[TBL] [Abstract][Full Text] [Related]
55. Novel formulation of a methotrexate derivative with a lipid nanoemulsion.
Moura JA; Valduga CJ; Tavares ER; Kretzer IF; Maria DA; Maranhão RC
Int J Nanomedicine; 2011; 6():2285-95. PubMed ID: 22072866
[TBL] [Abstract][Full Text] [Related]
56. Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents.
Corbin IR; Li H; Chen J; Lund-Katz S; Zhou R; Glickson JD; Zheng G
Neoplasia; 2006 Jun; 8(6):488-98. PubMed ID: 16820095
[TBL] [Abstract][Full Text] [Related]
57. Influence of liver cancer on lipid and lipoprotein metabolism.
Jiang J; Nilsson-Ehle P; Xu N
Lipids Health Dis; 2006 Mar; 5():4. PubMed ID: 16515689
[TBL] [Abstract][Full Text] [Related]
58. High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells.
Lou B; Liao XL; Wu MP; Cheng PF; Yin CY; Fei Z
World J Gastroenterol; 2005 Feb; 11(7):954-9. PubMed ID: 15742395
[TBL] [Abstract][Full Text] [Related]
59. Low density lipoprotein as a carrier of cytostatics in cancer chemotherapy: study of stability of drug-carrier complexes in blood.
Masquelier M; Vitols S; Pålsson M; Mårs U; Larsson BS; Peterson CO
J Drug Target; 2000; 8(3):155-64. PubMed ID: 10938525
[TBL] [Abstract][Full Text] [Related]
60. Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice.
Masquelier M; Vitols S; Peterson C
Cancer Res; 1986 Aug; 46(8):3842-7. PubMed ID: 3731059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
